Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: The DILIPO study

Doron Aronson; Joseph Verbalis; Matthias Mueller; Henry Krum

doi:10.1093/eurjhf/hfq226

Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: The DILIPO study

Doron Aronson, Joseph Verbalis, Matthias Mueller, Henry Krum

Epidemiology and Preventive Medicine Alfred Hospital

Research output: Contribution to journal › Article › Research › peer-review

35 Citations (Scopus)

Abstract

Arginine vasopressin (AVP) V2 receptor antagonism is a new approach to the management of hyponatraemia in congestive heart failure (CHF). The aim of this study was to investigate the efficacy and safety of satavaptan, an oral AVP V2-receptor antagonist, in patients with dilutional hyponatraemia.

Original language	English
Pages (from-to)	327 - 336
Number of pages	10
Journal	European Journal of Heart Failure
Volume	13
Issue number	3
DOIs	https://doi.org/10.1093/eurjhf/hfq226
Publication status	Published - 2011

Access to Document

10.1093/eurjhf/hfq226

Cite this

@article{b9aa54c817ca43cbb6b6731e1b53d504,

title = "Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: The DILIPO study",

abstract = "Arginine vasopressin (AVP) V2 receptor antagonism is a new approach to the management of hyponatraemia in congestive heart failure (CHF). The aim of this study was to investigate the efficacy and safety of satavaptan, an oral AVP V2-receptor antagonist, in patients with dilutional hyponatraemia.",

author = "Doron Aronson and Joseph Verbalis and Matthias Mueller and Henry Krum",

year = "2011",

doi = "10.1093/eurjhf/hfq226",

language = "English",

volume = "13",

pages = "327 -- 336",

journal = "European Journal of Heart Failure",

issn = "1388-9842",

publisher = "Wiley-Blackwell",

number = "3",

}

Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: The DILIPO study. / Aronson, Doron; Verbalis, Joseph; Mueller, Matthias; Krum, Henry.

In: European Journal of Heart Failure, Vol. 13, No. 3, 2011, p. 327 - 336.

Research output: Contribution to journal › Article › Research › peer-review

TY - JOUR

T1 - Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: The DILIPO study

AU - Aronson, Doron

AU - Verbalis, Joseph

AU - Mueller, Matthias

AU - Krum, Henry

PY - 2011

Y1 - 2011

N2 - Arginine vasopressin (AVP) V2 receptor antagonism is a new approach to the management of hyponatraemia in congestive heart failure (CHF). The aim of this study was to investigate the efficacy and safety of satavaptan, an oral AVP V2-receptor antagonist, in patients with dilutional hyponatraemia.

AB - Arginine vasopressin (AVP) V2 receptor antagonism is a new approach to the management of hyponatraemia in congestive heart failure (CHF). The aim of this study was to investigate the efficacy and safety of satavaptan, an oral AVP V2-receptor antagonist, in patients with dilutional hyponatraemia.

UR - http://eurjhf.oxfordjournals.org/content/13/3/327.full.pdf+html

U2 - 10.1093/eurjhf/hfq226

DO - 10.1093/eurjhf/hfq226

M3 - Article

VL - 13

SP - 327

EP - 336

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 3

ER -

Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: The DILIPO study

Abstract

Access to Document

Other files and links

Cite this